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Abstract 
The capacity of patients infected with human immunodeficiency virus (HIV) to develop an adequate antibody response to influenza 
vaccination in relation to the CD4 cell count has been studied in a prospective study. A total of 73 subjects (54 HIV-infected patients 
and 19 healthy control persons) were vaccinated with influenza subunit vaccine containing 1.5 pug hemagglutinin of each of the 
following strains: A/Beijing/353/89(H3N2), A/Singapore/6/86(HlNl), B/Panama/45/90, and B/Beijing/i/87. Hemagglutinin inhibition 
(HI) antibody titers were determined prior to vaccination, 3 weeks afterwards, and at the end of the influenza season.The percentage 
of subjects with HI antibody titers above the assumed protective level was significantly lower in the HIV-infected patients for all 
4 vaccine strains compared with those in the control group (7-26% and 42-74%, respectively). There was an association between 
CD4 cell count and antibody response to the B/Panama strain only.The serologic response to tetravalent subunit influenza vaccine 
is severely impaired in the majority of HIV-infected patients compared with control subjects. The results of this study challenges 
the recommendation to vaccinate HIV-infected patients. 
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1. Introduction 
Influenza causes increased morbidity and mortality in 
the elderly and patients with certain chronic diseases 
[l-4]. The influenza incidence is low among adults and 
HIV-related immunodeficiency seems to increase the in- 
fluenza risks only minimally [5,6]. However since the 
pandemic occurrence of the human immunodeficiency 
virus type 1 (HIV) in the 1980s it has been discussed 
whether subjects carrying HIV, have an increased risk of 
serious complications after an acute influenza infection 
[7,8]. Therefore the Public Health Service Advisory 
Committee on Immunization Practices has been advising 
influenza vaccination in HIV-infected patients as a ‘pru- 
dent precaution’ [2,9]. 
*Corresponding author. Te1.(+31-30) 250 9111; Fax (+31-30) 251 8328. 
The ability of HIV-infected patients to produce suffi- 
cient protective antibody to influenza vaccine has been 
disputed. Only one study found that asymptomatic HIV- 
infected patients, patients with generalized lymphadeno- 
pathy and patients with AIDS-related complex had a 
normal antibody response to influenza vaccination [lo]. 
In contrast, several other studies showed antibody levels 
to be lower in HIV-infected patients after a single dose 
of influenza vaccine, even in asymptomatic subjects with 
minimally decreased CD4 cell counts, than in healthy 
control subjects [l l-141; the degree of impairment corre- 
lated with the severity of immunologic dysfunction [15]. 
Booster vaccination after four weeks did not improve the 
prevalence of assumed protective antibody levels [14]. 
The effect of HIV on the persistence of antibodies in- 
duced by influenza vaccine has not been studied yet. 
Studies which present data on short- and long-term 
0924-8579/96/$32.00 0 1996 Elsevier Science B.V. All rights reserved 
SSDI 0924-8579(95)00038-O 
196 M. M. E. Schneider et al. /International Journal of Antimicrobial Agents 6 (1996 ) 195-200 
side effects of inactivated influenza vaccine in HIV carri- and after the winter season 1991-1992 (postseason). 
ers show that the vaccine is safe: direct side effects (local CD4 cell counts were performed within 3 weeks of vacci- 
and systemic reactions) are negligible [ 10,l 1,141. nation. 
Thus, in view of these unanswered questions regarding 
influenza vaccination, the current study was conducted 
to assess the efficacy of a single dose of tetravalent influ- 
enza subunit vaccine to induce an antibody response in 
HIV-infected patients compared with healthy adults. 
The antibody response in relation to the concentration 
of CD4 lymphocytes in peripheral blood was examined. 
We also determined the antibody titers after the influ- 
enza season, to provide serologic evidence of infection 
with natural influenza and to establish the persistence of 
vaccine-induced antibodies with time. Side effects were 
not monitored in this study. 
2.3. Laboratory tests 
For antibody determination, sera were coded, sepa- 
rated, and kept frozen at -20°C within 24 hours after 
blood collection. The sera were tested in a blinded fash- 
ion, simultaneously, and in duplicate by using a hemag- 
glutination inhibition (HI) assay, with two-fold dilution 
steps [17]. The strains used in the titrations were the 
4 vaccine strains, and 2 endemic strains, A/Ned/9681 
92(HlNl) and A/Ned/969/92(H3N2), isolated during the 
1991-92 outbreak of influenza in the Netherlands. Influ- 
enza B strains were treated with ether according to Berlin 
et al. [18]. 
2. Materials and methods 
2.4. Calculations and statistical analysis 
2.1. Study population 
Volunteers were recruited in November 1991 and were 
included when they were not taking immunosuppressive 
agents (other than antiretroviral drugs), were not known 
to be hypersensitive to eggs, had no history of anaphylac- 
tic reaction to influenza vaccine, and were not pregnant 
or lactating. The history of previous influenza vaccina- 
tions was recorded for all participants. 
The HIV seropositive group consisted of patients who 
were positive for anti-HIV type l-antibody (enzyme- 
linked immunoabsorbent assay and Western blot) and 
who were being treated in the HIV outpatient clinic of 
the University Hospital Utrecht, The Netherlands. The 
stage of the HIV disease was determined according to the 
criteria of the Centers for Disease Control and Preven- 
tion [16]. The control subjects were recruited from the 
house staff of the University Hospital Utrecht without 
additional selection. 
The study design was approved by the Investigational 
Review Board of the University Hospital Utrecht. All 
patients gave their informed consent. 
HI titers are expressed as the reciprocals of the dilu- 
tion showing 50% inhibition of hemagglutination with 
three hemagglutination units of the antigen. Titers be- 
tween 0 and 9 were arbitrarily regarded as 5. With the 
method used, protection against infection, for the im- 
munocompromised patients and the control subjects, is 
assumed to be associated with a HI titer 2 100 for influ- 
enza A strains [19] and ~200 for influenza B strains [20]. 
Percentiles were calculated and differences between 
groups were tested with the Wilcoxon rank sum test. 
Differences in response between the HIV patients and 
controls were tested with Chi-square and Fisher exact. 
The association between CD4 cell count and antibody 
response was tested with Chi-square for trend. For this 
purpose patients were categorized in three groups ac- 
cording to their CD4 cell count: group 1 with a CD4 cell 
count s200/mm3, group 2 with a CD4 cell count between 
200-500/mm3, and group 3 with a CD4 cell count ~5001 
mm3. 
2.2. Vaccine and study design 
A P-value of 0.05 or less was considered to indicate 
statistical significance. Confidence intervals had 95% 
limits. All calculations were done on a personal com- 
puter using the SAS computer program [21]. 
Tetravalent influenza subunit vaccine (Solvay-Duphar 
B.V., The Netherlands) for the 1991-1992 season con- 
tained 15 microgram hemagglutinin of each of the fol- 
lowing strains: A/Beijing/353/89(H3N2), A/Singapore/6/ 
86(HlNl), and B/Panama/45/90, B/Beijing/i/87, in 0.5 
ml aqueous solution. The vaccine composition was ac- 
cording to the advice of the Dutch Health Council and 
recommendation of the World Health Organization. 
Each subject received an intramuscular injection of one 
dose in the right or left deltoid muscle. Venous blood 
specimens were drawn immediately before vaccination 
(prevaccination), 3 weeks afterwards (postvaccination), 
3. Results 
3.1. Study population 
A total of 82 subjects were enrolled in the study in 
November 199 1. Sixty-two persons were HIV-seroposi- 
tive patients and 20 persons were healthy controls. All 
subjects were immunized with tetravalent influenza sub- 
unit vaccine. 
Both pre- and postvaccination blood specimens were 
available from 73 participants. The second blood speci- 
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men was missing of seven HIV-seropositive patients and 
of one control subject, because of noncompliance. The 
prevaccination sample of one HIV-seropositive patient 
was lost. The HIV-seropositive group (n = 54) and the 
control group (n = 19) were balanced with respect o age, 
time period between pre- and postvaccination serum 
samples, and previous vaccinations (Table 1). The HIV 
seropositive group contained 51 males and 3 females, 
whereas the control group contained 14 males and 5 fe- 
males (Table 1). In contrast to the 19 control subjects, 
who were heterosexual, 48 of the 54 HIV infected pa- 
tients were homosexual (Table 1). 
The distribution of HIV+eropositive patients accord- 
ing to the CDC classification [15] resulted in 19 patients 
in class II, 7 patients in class III, 20 patients in classes 
IVCl and IVC2, and 8 patients in classes IVA, B, D and 
E. CDC classes II and III were associated with higher 
CD4 cell counts and a lower treatment percentage with 
antiretroviral agents (Table 1). CDC classification and 
CD4 cell count were not affected by age or previous 
vaccinations. Antiretroviral therapy was significantly 
correlated with low CD4 cell counts. 
3.2. Vaccine-induced HI antibodies 
Serum hemagglutin inhibition (HI) antibody titers be- 
fore vaccination differed between the two study groups. 
Table 1 
Base-line characteristics of the study groups 
Variable Patients Controls 
No. of patients 54 19 
Age (years) 
Mean 
Range 
Male sex 
Risk factors for HIV infection 
Homosexual or bisexual 
i.v. drugs or receipt of bloodproducts 
No. of patients with previous vaccinations 
against influenza 
Time (days) between pre- and post- 
vaccination samples 
Mean 
Range 
CD4 cell count (per mm’) 
Median 
Range 
Disease stage (No. of patients using 
antiretroviral drugs) 
II 
III 
IV Cl-c2 
IV A, B, D, E 
39 
2464 
51154 
46 
8 
4 
23 21 
15-37 2G-30 
179 697 
2-1550 317-1079 
19 (3) 
7 (1) 
20 (17) 
g (6) 
35 
2442 
14/19 
However, in both HIV-seropositive patients and control 
subjects prevaccination titers were below the assumed 
protective level for all four vaccine strains (Table 2). 
These low prevaccination titers were to be expected, be- 
cause none of the healthy adults and only four of the 
HIV-infected patients were vaccinated previously. 
Postvaccination titers were significantly lower for all 
4 vaccine strains in the HIV-seropositive group com- 
pared with the control group (A/Singapore (HlNl), 
P = 0.001; A/Beijing (H3N2), P = 0.004; B/Panama, 
P = 0.0001, and B/Beijing, P = 0.0001; Table 2). 
The percentage of subjects with HI titers above the 
assumed protected level was low in the HIV patients 
compared with the controls, for all four vaccine strains 
(A/Beijing (H3N2), A/Singapore (HlNl), B/Panama, 
and B/Beijing: 17%, 13%, 26% and 7%, and 53%, 63%, 
74% and 42%, respectively, Table 3). 
The antibody response was significantly lower in the 
HIV-infected patient than in the controls. There was no 
significant association between CD4 cell count and the 
antibody response, except for the response to the B/Pan- 
ama strain. In HIV patients with a CD4 cell count 2500 
per mm3, 4 out of 10 patients responded to vaccination 
of the B/Panama strain; in patients with CD4 cell count 
between 200 and 500 per mm3, 6 out of 15 responded, but 
in patients with a CD4 cell count 1200 per mm3, only 
4 out of 29 responded (Table 3). 
The use of antiretroviral therapy was highly related to 
CD4 cell count and was not an independent factor affect- 
ing the antibody response. Previous vaccination did not 
affect the postvaccination antibody response as was ex- 
pected because of the small number of previously vacci- 
nated subjects. 
3.3. Incidence of infections during influenza season 
Postseason blood specimens were available for 59 of 
the 73 participants (collected 111-169 days after the 
postvaccination specimens). Fourteen patients in the 
HIV-seropositive group dropped out. Seven HIV-sero- 
positive patients died of AIDS and 6 HIV-infected pa- 
tients were noncompliant. Blood samples from 1 patient 
were lost. 
More than four-fold titer rises between postvaccina- 
tion and postseason sera, a conventionally accepted cri- 
terium for an infection in the period between the two 
blood samples [19], occurred in 2 of 58 HIV-infected 
patients (3%) and 1 of 18 control subjects (6%) for the 
A-H3N2 strain, which indeed circulated in The Nether- 
lands during the winter season. There was no evidence 
for a difference in the incidence of infection between HIV 
infected patients and control subjects. 
3.4. Antibody persistence 
To assess the decrease of HI antibody titer with time, 
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Table 2 
Serum hemagglutination i hibition antibody titers to tetravalent influenza subunit vaccine before, 3 weeks after vaccination and at the end of the 
influenza season 
A/Singapore A/Beijing B/Panama B/Beijing 
Sl s2 s3 Sl s2 s3 Sl s2 s3 Sl s2 s3 
HIV patients N=54 N=54 N=40 N=54 N=54 N = 40 N=54 N=54 N=40 N= 54 N= 54 N=40 
Median 5 9 5 5 24 5 12 51 26 5 12 6 
P25-15* 5-5 543 5-15 5-5 5-54 5-26 5-34 15-242 12-65 5-5 5-96 5-12 
mean 11 42 20 11 93 43 52 213 88 9 58 20 
Controls N= 19 N= 19 N= 19 N=19 N=19 N= 19 N=19 N=19 N= 19 N= 19 N= 19 N= 19 
Median 5 192 108 5 106 48 68 626 484 8 96 82 
P25p75 5-12 96384 48-272 5-5 22-272 15-136 12-96 192-1935 121-968 5-19 48-1219 24-610 
Mean 12 398 641 7 181 145 62 1583 1069 24 634 543 
P-value** p = 0.001 p = 0.0001 p = 0.004 p = 0.0002 p = 0.0001 p = 0.0001 p = 0.0001 p = 0.0001 
Sl: serum HI antibody titers prevaccination; S2: serum HI antibody titers 3 weeks after vaccination; S3: serum HI antibody titers at the end of the 
influenza season. 
*P25 = 25th Percentile; P75 = 75th Percentile. 
**P-value represents the difference between the titer measured in HIV-infected patients and the one measured in controls. 
subjects were identified, of whom HI antibody titers were 
available 3 weeks after vaccination and at the end of the 
season (40 HIV-infected patients and 19 control sub- 
jects). Subsequently the difference between the postsea- 
son (S3) HI antibody titers and the postvaccination (S2) 
titers of the HIV-infected patients were compared to the 
difference between those titers (S2 and S3) of the control 
subjects for each vaccine strain. The differences in HI 
antibody titers between S2 and S3 were equal in controls 
and HIV-infected patients for any of the vaccine strains 
except for the Influenza A/Singapore strain (P = 0.05). 
4. Discussion 
This study shows that HIV-infected patients have a 
severely impaired antibody response to tetravalent influ- 
enza subunit vaccine compared to control persons. The 
median postvaccination titers of hemagglutination inhi- 
bition (HI) antibodies to all 4 vaccine strains, (A/Beijing/ 
353/89 (H3N2), A/Singapore/6/86(HlNl), B/Panama/ 
45/90, and B/Beijing/l/87 were significantly lower in 
HIV-infected patients than in control subjects (Table 2). 
Moreover the percentage of subjects with postvaccina- 
tion HI antibody titers above the assumed protective 
level was also significantly lower in the HIV-infected 
group than in the control group (7-26% and 42-74%, 
respectively; Table 3). Remarkably all HIV-infected pa- 
tients had low HI antibody titers postvaccination, inde- 
pendent of the subgroup, according to their CD4 cell 
count, they were divided in (Table 3). This finding seems 
to be in contrast to several earlier reports, which found 
that HIV patients with higher CD4 cell counts (and/or 
patients who are asymptomatic have a better response 
[10,14]. We statistically analyzed the influence of several 
demographic and clinical variables on these postvaccina- 
tion titers. First, the HIV-infected patients differed from 
the controls with respect o the proportion of homosexu- 
als and heterosexuals (Table 1). Several studies showed 
a difference in postvaccination HI antibody titers to 
some strains of the influenza vaccine between homosex- 
ual and heterosexual HIV-seronegative males [13-141. 
However, the clinically more relevant percentage of sub- 
jects with assumed protective postvaccination HI anti- 
body titers seemed not significantly different in those 
studies. Therefore, the difference in the proportion of 
homosexual subjects probably did not have a significant 
influence on the outcome of the current study. Second, 
Table 3 
The number (%) of HIV-infected patients with hemaglutination i hibition titers above the assumed protective level after influenza vaccination, 
categorized in three groups according to their CD4 cell count. 
CD4 5 200 CD4 = 201499 CD4 2 500 Chi-square for trend Total HIV patients 
Control Chi-square 
A/Singapore 2129 4115 l/10 NS 7/54 (13) 12119 (63) p c 0.0001 
A/Beijing 3129 6115 0110 NS 9154 (17) 10119 (53) p = 0.002 
B/Panama 4129 6115 4/10 P = 0.05 14/54 (26) 14/19 (74) p < 0.0001 
B/Beijing 1129 2115 l/10 NS 4154 (7) S/19 (42) p < 0.0001 
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the prevaccination HI antibody titers significantly af- 
fected the level of postvaccination titers, as was expected. 
However, although prevaccination titers differed be- 
tween the two study groups, all prevaccination titers 
were below the assumed protective level (Table 2). After 
elimination of the influence of prevaccination titers on 
the postvaccination titers the differences between the two 
study groups with respect to all 4 vaccine strains re- 
mained significant. The impairment of the antibody re- 
sponse after vaccination in HIV-infected patients was 
more severe in patients in CDC class IV, than in patients 
in CDC classes II and III. This confirms the results of 
previous studies [11,13-141. Finally, there were no differ- 
ences in the postvaccination HI antibody titers between 
HIV-infected patients who used antiretroviral drug ther- 
apy and HIV-infected patients who did not receive these 
drugs. Thus, the use of antiretroviral therapy did not 
affect the antibody response to influenza vaccination in 
this study group. 
HI antibody titers were also measured at the end of the 
influenza season. Postseason vaccination titers were 
lower in both study groups. There was no significant 
difference between the two study groups with respect o 
the decrease of HI antibody titers between 3 weeks after 
vaccination and at the end of the season, except possibly 
for the A/Singapore strain. 
Although this study was. not designed to assess the 
incidence of natural influenza infection during the winter 
of 1991-92, the available data showed that the HIV- 
infected patients did not have a higher incidence of natu- 
ral infections than the controls subjects (3% versus 6%, 
respectively). However, given the low rate of break- 
through infections and the small number of participants, 
the study power may have been to low to show a differ- 
ence in protection if it was present. 
In our study, the impairment of antibody response in 
all HIV-infected patients to influenza vaccine, independ- 
ent of their CD4 cell count was much more severe than 
in other studies published so far [lo-141. This heterogen- 
icity among studies has already been described for influ- 
enza research in other patient groups [22,23]. Earlier, the 
influenza vaccine was reported to have no deleterious 
effect on the level of serum p24 antigen or the CD4 cell 
count [10,11,14]. However a recent study showed that 
HIV patients had a statistically significant higher num- 
ber of plasma HIV copies/ml, one month after influenza 
vaccination than HIV patients who were vaccinated with 
placebo-vaccine. Furthermore 3 months after vaccina- 
tion, CD4% dropped in the vaccine recipients and had 
risen slightly in the control group [24]. The question 
therefore arises if routine vaccination of any HIV-in- 
fected patients is warranted at all, given its low efficacy 
and the probability of increased plasma HIV burden 
after vaccination. However additional chemoprophy- 
laxis with amantadine or ri:mantadine should be consid- 
ered during an influenza A outbreak. 
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